Effect of Implementing Evidence-based Practice and Nurse's Behavior Change on Quality of C
Quality of care is crucial for preventing adverse events such as infection in the intensive care units (ICUs). The most common ICU-acquired infections include pneumonia such as ventilator-associated pneumonia (VAP), Central Line Bloodstream Infection (CLABSI), catheter-associated urinary tract in, Medical Device Relate
| Condition(s) | Ventilator Associated Pneumonia (VAP), Evidence Based Practice |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Quality of care is crucial for preventing adverse events such as infection in the intensive care units (ICUs). The most common ICU-acquired infections include pneumonia such as ventilator-associated pneumonia (VAP), Central Line Bloodstream Infection (CLABSI), catheter-associated urinary tract in, Medical Device Related Pressure Ulcer (MDRPU) and Pressure Ulcer (PU). This study explores the patient outcome in ICU by examining the causes and prevalence of ICU-acquired infection. The implementation of evidence-based practice (EBP) to reduce infection and change the nurses practice (behavioral changes) to adhere with EBP based on simulation-based training. General objective: To evaluate the effect of EBP by using recent technologies-based equipment to prevent VAP and promote behavior change a |
| Who can participate | Study 2: Inclusion criteria: * Who will be a registered nurse in Bangladesh. * Who will agree to participate in this study and the EBP training. Exclusion criteria: * Who will not directly involve patient care in ICU. Study 3: Inclusion Criteria: * Irrespective of age and sex, participant must be 18 years old. * Legal guardian of a patient consents to participation in the study * Intubated patients after admission. Exclusion Criteria: * Who stays less than 2 days at the GICU. * Who dies or is extubated within 2 days after admitted in the GICU. * ICU readmission. |
| Ages | 18 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | Hiroshima University |
| Locations | Dhaka, Bangladesh; Hiroshima, Kasumi 1-2-3 Minami-ku, Japan |
| Start date | 2024-10-10 |
| NCT ID | NCT06624540 |
| Official listing | https://clinicaltrials.gov/study/NCT06624540 |